Floatz logo

Defactinib

Low Grade Ovarian Serous Adenocarcinoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

114 Active assets in the Low Grade Ovarian Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Letrozole
Memorial Sloan Kettering Cancer Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Defactinib is also rated in:

ovarian serous adenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →
KRAS Activating MutationDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →